Poster
62
(#62) Real-World Disability Outcomes Among Patients Treated With Cariprazine Versus Quetiapine as Adjunctive Treatment for Major Depressive Disorder
Psych Congress 2025
Abstract: Background: Major depressive disorder (MDD) is associated with substantial disability burden. We compared real-world disability days, claims, and costs among patients with MDD initiating adjunctive treatment with cariprazine or quetiapine.
Methods: The MerativeTM MarketScan® Commercial Database and the Health and Productivity Management Database (1/1/2015-12/31/2022) were used to identify adults with MDD and ≥2 pharmacy claims for cariprazine or quetiapine (first dispensing=index) adjunctive to antidepressant therapy. Baseline characteristics were balanced between treatment cohorts via inverse probability of treatment weighting. Outcomes included all-cause and mental health (MH)-related disability days and claims (per person-year [PPY]) and costs (per person per year [PPPY]). Disability outcomes were compared using adjusted rate ratios (RRs) and mean cost differences with 95% CIs and P-values using nonparametic bootstrap procedures.
Results: The cariprazine and quetiapine cohorts included 200 and 749 patients, respectively. All-cause disability days PPY were significantly lower for cariprazine versus quetiapine (adjusted RR [95% CI]: 0.42 [0.20, 0.85], P=.016). Rates of MH-related days, all-cause claims, and MH-related claims PPY were not significantly different. Both all-cause and MH-related disability costs PPPY were significantly lower for cariprazine versus quetiapine (adjusted mean cost difference [95% CI]: all cause = -$3,678.87 [-5,978.80, -1,333.33], P=.008; MH-related = -$2,577.17 [-4,285.47, -767.68], P=.008).
Conclusions: In this real-world analysis of patients with MDD, adjunctive cariprazine was associated with significantly lower rates of all-cause disability days as well as all-cause and MH-related disability costs versus adjunctive quetiapine. These results suggest that adjunctive cariprazine may improve disability outcomes compared to quetiapine in patients with MDD.
Short Description: This real-world, claims-based analysis evaluated the rates of disability days, claims, and costs among patients with major depressive disorder (MDD) treated with adjunctive cariprazine or quetiapine. Compared with adjunctive quetiapine, adjunctive cariprazine was associated with a significantly lower rate of all-cause disability days as well as significantly lower rates of all cause and mental health-related disability costs, suggesting that adjunctive cariprazine may have beneficial effects on disability outcomes in patients with MDD.
Name of Sponsoring Organization(s): AbbVie
Methods: The MerativeTM MarketScan® Commercial Database and the Health and Productivity Management Database (1/1/2015-12/31/2022) were used to identify adults with MDD and ≥2 pharmacy claims for cariprazine or quetiapine (first dispensing=index) adjunctive to antidepressant therapy. Baseline characteristics were balanced between treatment cohorts via inverse probability of treatment weighting. Outcomes included all-cause and mental health (MH)-related disability days and claims (per person-year [PPY]) and costs (per person per year [PPPY]). Disability outcomes were compared using adjusted rate ratios (RRs) and mean cost differences with 95% CIs and P-values using nonparametic bootstrap procedures.
Results: The cariprazine and quetiapine cohorts included 200 and 749 patients, respectively. All-cause disability days PPY were significantly lower for cariprazine versus quetiapine (adjusted RR [95% CI]: 0.42 [0.20, 0.85], P=.016). Rates of MH-related days, all-cause claims, and MH-related claims PPY were not significantly different. Both all-cause and MH-related disability costs PPPY were significantly lower for cariprazine versus quetiapine (adjusted mean cost difference [95% CI]: all cause = -$3,678.87 [-5,978.80, -1,333.33], P=.008; MH-related = -$2,577.17 [-4,285.47, -767.68], P=.008).
Conclusions: In this real-world analysis of patients with MDD, adjunctive cariprazine was associated with significantly lower rates of all-cause disability days as well as all-cause and MH-related disability costs versus adjunctive quetiapine. These results suggest that adjunctive cariprazine may improve disability outcomes compared to quetiapine in patients with MDD.
Short Description: This real-world, claims-based analysis evaluated the rates of disability days, claims, and costs among patients with major depressive disorder (MDD) treated with adjunctive cariprazine or quetiapine. Compared with adjunctive quetiapine, adjunctive cariprazine was associated with a significantly lower rate of all-cause disability days as well as significantly lower rates of all cause and mental health-related disability costs, suggesting that adjunctive cariprazine may have beneficial effects on disability outcomes in patients with MDD.
Name of Sponsoring Organization(s): AbbVie
